全球抗肿瘤抗体药物研究热点分析

Development trends of global antineoplastic antibody

分析了近10年全球抗肿瘤单克隆抗体核心文献的研究主题,通过研究主题的演变揭示领域发展趋势,确定近年来7个热点研究方向。通过专业数据库及机构网站对具体热点方向进行深度分析,挖掘国内外处于临床试验阶段及已上市药品的靶点、作用机制等相关信息。研究发现,已上市抗体药物有效性和安全性监测及药物联用、双特异性抗体及抗体药物偶联物等新型抗体药物研发,以及以4-1BB为代表的新靶点开发是近年来的研究热点和重点。中国应加强对上市药品的不良事件监测,加大力度支持新型抗体药物的研发。

Immune checkpoint antibody drugs have opened up a new era in the field of tumor treatment since the 20th century.In 2021,the global market share of antitumor monoclonal antibody drugs has reached 62 billion US dollars.In recent years,domestic enterprises have also accelerated their development in this field.However,a big gap still exists between these enterprises and international pharmaceutical giants.In this context,it is of vital significance to fully grasp the international research and development trends and the panorama of the RD pipeline.The research topics of core articles in this research field in the past 10 years were analyzed,and the development trend of the field was revealed through the evolution of the research topics.Seven active research directions were identified.In-depth analysis of specific research directions was carried out through further data mining from professional databases and institutional websites.Comprehensive analysis indicated that three directions including the efficacy and safety surveillance of marketed antibody drugs and drug combination,new antibody drugs such as bispecific antibodies and antibody-drug conjugates,and new targets represented by 4-1BB have been the research hotspots and focuses in recent years.Adverse event monitoring of marketed drugs should be strengthened,and efforts should be stepped up to support the research and development of new antibody drugs.